

INTEGRATED SERVICES

Utilising the benefits of a high quality biology and medicinal chemistry organisation allows Evotec to offer cost effective solutions for integrated programmes from target to clinic. Capabilities and expertise span assay development, compound screening, fragment-based drug discovery, structure-based drug design, medicinal chemistry, *in vitro* and *in vivo* PK as well as early chemistry development. As a result, Evotec has established a successful track record in assisting biotech and pharmaceutical companies in developing small molecule therapeutics. Evotec's collaborations have resulted in the identification of over 100 lead series, 20 preclinical compounds and 15 clinical compounds.

OUR CAPABILITIES, SKILLS AND EXPERTISE

SCREENING	HIT-TO-LEAD	LEAD OPTIMIZATION	PRECLINICAL DEVELOPMENT	CLINICAL DEVELOPMENT
<ul style="list-style-type: none"> — Assay development and screening — Assay development — Ultra high throughput screening (HTS) — High content screening (HCS) — Electrophysiology — <i>In silico</i> screening technologies — Fragment based drug discovery 	<ul style="list-style-type: none"> — Medicinal chemistry — Hit expansion — Library design — High throughput chemistry — Protein-ligand crystallography — <i>In vitro</i> pharmacology — Early ADMET 	<ul style="list-style-type: none"> — Medicinal chemistry — <i>In vitro</i> pharmacology — Disease biology and target class expertise — Computational chemistry and structure-based drug design — <i>In silico</i> ADMET — ADMET and Zebrafish screening — Safety pharmacology, tox & <i>in vivo</i> pharmacology 	<ul style="list-style-type: none"> — Custom synthesis — Analytical development — Process R&D — Large scale synthesis — <i>In vivo</i> pharmacology 	<ul style="list-style-type: none"> — Clinical alliances — Clinical project management

Technology and scientific leadership applicable to numerous target classes such as ion channels, GPCRs, kinases, general enzyme targets, protein:protein interactions and nuclear hormone receptors.

Expertise in CNS, inflammation, oncology and metabolic diseases, as well as other therapeutic areas

BENEFITS

Access to cutting edge technologies such as fragment screening, HCS, computational chemistry, structural biology, etc

- EVOTEC'S COMPOUND LIBRARY, ASSAY DEVELOPMENT AND SCREENING PLATFORM**

 - ▶ — Provides the best quality hits, thus enabling rapid optimisation, even for the most challenging targets
 - Increases rate of finding true positive hit compounds, leading to savings in time and cost

- EVOTEC'S FRAGMENT-BASED DRUG DISCOVERY PLATFORM**

 - ▶ — Allows screening of challenging targets using multiple screening technologies
 - Increases speed and reduces attrition from target to clinic by using rational design
 - Identifies new chemical starting points for “well-screened” and/or challenging targets

- EVOTEC'S MEDICINAL CHEMISTRY PLATFORM**

 - ▶ — Track record of success with all major target classes and particular expertise in the following therapeutic area: CNS, inflammation, oncology and metabolic diseases
 - Delivers on clients' needs with over 20 preclinical candidates nominated and 15 compounds approved for clinical trials
 - Adds value as demonstrated by Evotec medicinal chemists being named inventors on > 120 client patents covering all major target classes and therapeutic areas

- EVOTEC'S COMPUTATIONAL AND STRUCTURAL BIOLOGY PLATFORM**

 - ▶ — Increases speed and decreases costs from target to clinic by reducing the number of compounds that need to be synthesised
 - Reduces potential attrition through highly predictive *in silico* screening
 - Ligand-based approaches for difficult-to-crystallise targets (e.g. Ion channels and GPCRs) allied to protein modelling, enabling a rational design strategy

- EVOTEC'S ADMET AND ZEBRAFISH PLATFORM**

 - ▶ — Reduces timelines by identifying and optimising early compounds with potential liabilities
 - Increases chances of success and reduces costs by prioritising better leads and identifying toxicity related issues early
 - Identifies superior back-up or follow-on compounds

Access to a validated and demonstrated track record

> 15 CLINICAL COMPOUNDS
> 20 DEVELOPMENT CANDIDATES

PROVEN ABILITY TO PROGRESS TARGETS TO PRECLINICAL DEVELOPMENT WITHIN 3 YEARS

Capable of providing cost efficient capacity whilst leveraging leading technology platform and scientific know-how

Fully integrated, experienced project management will increase the likelihood of success